Prostate Health Market worth $48.9 billion by 2026 at a CAGR of 6.0%

According to a new research report "Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecasts to 2026" published by MarketsandMarkets, the global prostate health market is projected to reach USD 48.9 billion by 2026 from USD 31.8 billion in 2021, at a CAGR of 9.0% during the forecast period. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The prostate gland (the prostate) is an organ of the male reproductive system. The three most common forms of prostate disease are inflammation (prostatitis), non-cancerous enlargement of the prostate (benign prostatic hyperplasia, or BPH), and prostate cancer. Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107055093 Growth in this market is primarily driven by the increasing prevalence of benign prostatic hyperplasia, increasing obesity, investments, funds, and grants for research in prostate health, an increase in the prevalence of prostate cancer, a surge in demand for hormone therapy drugs, emerging therapies for prostate cancer, and an increasing incidence of prostatitis.Browse in-depth TOC on "Prostate Health Market"124 – Tables11 – Figures99 – PagesNorth American prostate health market to dominate the market during the forecast periodNorth America dominated the prostate health market in 2020 and is expected to grow at an 7.6% CAGR during the forecast period. North America has been among the frontrunners in developing prostate health therapies in the healthcare industry. The market growth in the US (a major contributor to the North American prostate health market) can be mainly attributed to the growing target population, the high incidence of BPH, prostate cancer, and prostatitis, and the strong presence of medical device manufacturers. Additionally, favorable reimbursement policies, high disposable incomes, a strong healthcare infrastructure, research funding, and product launches have accelerated the growth of this market.Inquiry Before Buying @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=107055093 Some of the prominent players operating in the prostate health market are Eli Lilly and Company (US), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline plc. (UK), Abbott (US), and Astellas Pharma Inc. (Japan), and other players.The growing prevalence of prostate cancer and benign prostatic hyperplasia (BPH) is a major driver of the global prostate health market. According to the World Health Organization (WHO), prostate cancer is the most common type of cancer among men, with an estimated 1.3 million new cases and 359,000 deaths reported in 2018. Similarly, BPH is the most common prostate-related disorder, affecting over 200 million men worldwide. The increasing prevalence of these conditions is driving the demand for advanced prostate health-related treatments and products, thus driving the growth of the global prostate health market.